A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
OBJECTIVE
To define the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), the biological active (BA) dose and the pharmacokinetics (PK) of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa) when administered continuously as a once daily dose in patients with advanced, incurable solid tumours.


METHODS
Twenty-eight patients were enrolled in cohorts of three from three National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) centers. ZD1839 was given at doses from 150 to 800 mg daily orally and patients underwent a pretreatment and a 28 day post treatment tumor biopsy, while PK sampling was performed on days 8, 15, 22, 29, and a toxicity assessment every 28 days.


RESULTS
All twenty-eight patients were evaluable for non-hematological and hematological toxicity. Twenty-seven were evaluable for response. The MTD was not reached but DLT included reversible rash and diarrhea. One patient with urachal cancer had a transient 55% decrease in tumor size and two other patients (breast and non-small cell lung cancer) had minor responses; three additional patients had pharmacodynamic evidence of target effect. PK demonstrated steady state within the first 2 weeks of dosing and dose dependent exposure.


CONCLUSIONS
It appears that ZD 1839 at a dose of 800 m/day was tolerable, although some patients required dose modification for diarrhea. Doses above 250 m/day demonstrate biologic activity and could be consider for future study in a variety of EGFR positive tumor types.
Goss
G
G
Ottawa Regional Cancer Centre, Ottawa, Ontario K1H 1C4, Canada. glenwood.goss@orcc.on.ca
Hirte
H
H
Miller
W H
WH
Lorimer
I A J
IA
Stewart
D
D
Batist
G
G
Parolin
D A E
DA
Hanna
P
P
Stafford
S
S
Friedmann
J
J
Walsh
W
W
Mathews
S
S
Douglas
L
L
Seymour
L K
LK
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D002170:Canada; D066246:ErbB Receptors / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D000077156:Gefitinib; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib
Clin Cancer Res. 2000 Dec;6(12):4885-92
11156248
Arch Surg. 1986 Nov;121(11):1242-7
3535739
J Clin Oncol. 2002 May 1;20(9):2240-50
11980995
J Clin Oncol. 2002 Nov 1;20(21):4292-302
12409327
Int J Radiat Oncol Biol Phys. 1992;22(1):225-30
1309204
J Biol Chem. 1994 Jan 7;269(1):260-5
8276804
J Biol Chem. 1992 Feb 5;267(4):2714-22
1733967
Cancer Res. 1995 Dec 1;55(23):5536-9
7585629
Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):657-66
8824370
J Biol Chem. 1998 Jan 2;273(1):200-6
9417065
Science. 2004 Jun 4;304(5676):1497-500
15118125
Clin Pharmacokinet. 2001;40(4):297-306
11368294
Jpn J Cancer Res. 1985 Aug;76(8):663-6
2995289
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
J Biol Chem. 1991 Nov 15;266(32):22035-43
1657987
Ann Oncol. 1997 Dec;8(12):1197-206
9496384
Br J Cancer. 1986 Aug;54(2):265-9
3017396
Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47
10758303
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5724-9
9576951
Bioorg Med Chem Lett. 2001 Jul 23;11(14):1911-4
11459659
J Pharm Biomed Anal. 2002 Jun 20;29(1-2):221-8
12062681
Oncogene. 1994 Aug;9(8):2313-20
8036013
J Clin Oncol. 2002 Sep 15;20(18):3815-25
12228201
Growth Factors. 1991;4(4):305-16
1722417